Free Trial

Jazz Pharmaceuticals (JAZZ) Short Interest Ratio & Short Volume

Jazz Pharmaceuticals logo
$111.30 -0.78 (-0.70%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$111.31 +0.01 (+0.01%)
As of 08/8/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals Short Interest Data

Jazz Pharmaceuticals (JAZZ) has a short interest of 5.73 million shares, representing 9.92% of the float (the number of shares available for trading by the public). This marks a -2.39% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.2, indicating that it would take 6.2 days of the average trading volume of 771,387 shares to cover all short positions.

Current Short Interest
5,730,000 shares
Previous Short Interest
5,870,000 shares
Change Vs. Previous Month
-2.39%
Dollar Volume Sold Short
$643.48 million
Short Interest Ratio
6.2 Days to Cover
Last Record Date
July 15, 2025
Outstanding Shares
60,510,000 shares
Float Size
57,780,000 shares
Short Percent of Float
9.92%
Today's Trading Volume
893,673 shares
Average Trading Volume
771,387 shares
Today's Volume Vs. Average
116%
Short Selling Jazz Pharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

JAZZ Short Interest Over Time

JAZZ Days to Cover Over Time

JAZZ Percentage of Float Shorted Over Time

Jazz Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/20255,730,000 shares $643.48 million -2.4%9.9%6.2 $112.30
6/30/20255,870,000 shares $622.92 million +0.7%10.2%5.6 $106.12
6/15/20255,830,000 shares $632.56 million +2.1%10.1%5 $108.50
5/31/20255,710,000 shares $618.28 million -4.0%9.7%4.5 $108.28
5/15/20255,950,000 shares $631.12 million +11.2%10.1%4.4 $106.07
4/30/20255,350,000 shares $625.74 million +18.1%9.1%4.1 $116.96
4/15/20254,530,000 shares $466.18 million +5.8%7.8%4 $102.91
3/31/20254,280,000 shares $531.36 million -5.3%7.4%4.2 $124.15
3/15/20254,520,000 shares $623.58 million +3.7%7.8%5.4 $137.96
2/28/20254,360,000 shares $625.79 million -3.8%7.5%6 $143.53
2/15/20254,530,000 shares $606.84 million +7.4%7.9%7 $133.96
1/31/20254,220,000 shares $524.84 million -0.9%7.3%6.8 $124.37
1/15/20254,260,000 shares $525.00 million +10.7%7.4%7.2 $123.24
12/31/20243,850,000 shares $474.13 million -8.3%6.7%6.4 $123.15
12/15/20244,200,000 shares $516.77 million -1.2%7.3%6.9 $123.04
11/30/20244,250,000 shares $516.76 million +11.3%7.3%7 $121.59
11/15/20243,820,000 shares $464.70 million +6.4%6.6%5.4 $121.65
10/31/20243,590,000 shares $395.01 million +2.9%6.2%5.5 $110.03
10/15/20243,490,000 shares $409.31 million +3.3%5.9%5.1 $117.28
9/30/20243,380,000 shares $376.57 million +3.1%5.7%5.1 $111.41
9/15/20243,280,000 shares $356.83 million +73.5%5.5%4.8 $108.79
8/31/20241,890,000 shares $219.20 million -7.4%3.2%2.7 $115.98
8/15/20242,040,000 shares $224.40 million -10.9%3.4%2.8 $110.00
7/31/20242,290,000 shares $252.47 million -17.6%3.8%3 $110.25
7/15/20242,780,000 shares $287.26 million +3.7%N/A3.7 $103.33
6/30/20242,680,000 shares $286.04 million +4.7%N/A3.5 $106.73
6/15/20242,560,000 shares $289.05 million -24.9%N/A3.4 $112.91
5/31/20243,410,000 shares $358.90 million +4.0%N/A4.6 $105.25
5/15/20243,280,000 shares $359.95 million -8.9%N/A4.8 $109.74
4/30/20243,600,000 shares $398.70 million -2.7%N/A5.6 $110.75
4/15/20243,700,000 shares $410.37 million +13.5%6.1%6 $110.91
3/31/20243,260,000 shares $392.57 million +17.7%5.4%5.3 $120.42
3/15/20242,770,000 shares $334.89 million +15.9%4.6%4.3 $120.90
2/29/20242,390,000 shares $284.17 million +3.0%4.0%4 $118.90
2/15/20242,320,000 shares $294.22 million +5.0%N/A4 $126.82
1/31/20242,210,000 shares $271.21 million +2.3%N/A3.4 $122.72
1/15/20242,160,000 shares $256.91 million -1.8%N/A3 $118.94
12/31/20232,200,000 shares $270.60 million -0.5%N/A3.1 $123.00
12/15/20232,210,000 shares $268.52 million -9.1%N/A3.1 $121.50
11/30/20232,430,000 shares $287.30 million -5.5%N/A3.6 $118.23
The Coin That Could Define Trump’s Crypto Presidency (Ad)

When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”

Discover the coin that could define Trump’s crypto presidency.
11/15/20232,570,000 shares $322.28 million -6.2%N/A4 $125.40
10/31/20232,740,000 shares $348.03 million +5.0%N/A4.5 $127.02
10/15/20232,610,000 shares $337.00 million -19.9%N/A4.7 $129.12
9/30/20233,260,000 shares $421.97 million -2.4%N/A6.9 $129.44
9/15/20233,340,000 shares $442.52 million +16.8%N/A6.8 $132.49
8/31/20232,860,000 shares $410.01 million +1.1%N/A5.4 $143.36
8/15/20232,830,000 shares $396.17 million -0.4%N/A5 $139.99
7/31/20232,840,000 shares $370.39 million -5.7%N/A5 $130.42
7/15/20233,010,000 shares $381.34 million +0.3%N/A5.3 $126.69
6/30/20233,000,000 shares $371.91 million +11.5%N/A5.4 $123.97
6/15/20232,690,000 shares $346.82 million -13.8%N/A5.1 $128.93
5/31/20233,120,000 shares $399.86 million +5.1%N/A6.3 $128.16
5/15/20232,970,000 shares $400.00 million +19.8%N/A6 $134.68
4/30/20232,480,000 shares $348.37 million +7.4%N/A5 $140.47
4/15/20232,310,000 shares $336.15 million -10.1%N/A4.8 $145.52
3/31/20232,570,000 shares $376.07 million +10.8%N/A5 $146.33
3/15/20232,320,000 shares $312.94 million -4.9%N/A4.4 $134.89
2/28/20232,440,000 shares $342.58 million -1.6%N/A4.2 $140.40
2/15/20232,480,000 shares $370.54 million -3.9%N/A4.6 $149.41
1/31/20232,580,000 shares $404.18 million -1.9%N/A4.6 $156.66
1/15/20232,630,000 shares $411.52 million -2.6%N/A4.8 $156.47
12/30/20222,700,000 shares $430.14 million +21.1%N/A5 $159.31
12/15/20222,230,000 shares $341.10 million +2.8%N/A4 $152.96
11/30/20222,170,000 shares $340.49 million -7.7%N/A4 $156.91
11/15/20222,350,000 shares $348.83 million -1.7%N/A4.5 $148.44
10/31/20222,390,000 shares $343.66 million +6.2%N/A4.7 $143.79
10/15/20222,250,000 shares $299.72 million -14.1%N/A4.3 $133.21
9/30/20222,620,000 shares $349.22 million -4.4%N/A5 $133.29
9/15/20222,740,000 shares $416.97 million -1.4%N/A5.3 $152.18
8/31/20222,780,000 shares $431.51 million No ChangeN/A5.7 $155.22
8/15/20222,780,000 shares $445.52 million +3.0%N/A5.4 $160.26
7/31/20222,700,000 shares $421.36 million -9.7%4.5%5.2 $156.06
7/15/20222,990,000 shares $470.75 million +2.8%4.9%5.8 $157.44
6/30/20222,910,000 shares $453.99 million -4.9%4.8%5.4 $156.01
6/15/20223,060,000 shares $446.09 million -13.8%5.1%5.5 $145.78
5/31/20223,550,000 shares $531.36 million +10.6%5.9%6.7 $149.68
5/15/20223,210,000 shares $470.23 million -2.7%5.3%5.5 $146.49
4/30/20223,300,000 shares $528.73 million -12.2%5.6%5.6 $160.22
4/15/20223,760,000 shares $628.86 million +4.7%6.3%6.6 $167.25
3/31/20223,590,000 shares $558.86 million -5.0%6.0%5.7 $155.67
3/15/20223,780,000 shares $584.88 million -6.9%6.3%6.2 $154.73
2/28/20224,060,000 shares $557.93 million -6.0%6.8%6.4 $137.42
2/15/20224,320,000 shares $624.11 million +0.9%7.2%7 $144.47
1/31/20224,280,000 shares $594.53 million +3.9%7.2%6.9 $138.91
1/15/20224,120,000 shares $594.52 million -7.2%6.9%6.7 $144.30
12/31/20214,440,000 shares $565.66 million +0.7%7.4%7.4 $127.40
12/15/20214,410,000 shares $536.83 million +9.7%7.4%7.4 $121.73
11/30/20214,020,000 shares $481.88 million -2.7%6.7%6.4 $119.87
11/15/20214,130,000 shares $574.81 million +7.8%6.9%6.6 $139.18
10/29/20213,830,000 shares $509.54 million No Change6.4%5.8 $133.04
The Coin That Could Define Trump’s Crypto Presidency (Ad)

When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”

Discover the coin that could define Trump’s crypto presidency.
10/15/20213,830,000 shares $538.88 million +7.6%6.4%5.4 $140.70
9/30/20213,560,000 shares $463.55 million -1.1%6.0%5 $130.21
9/15/20213,600,000 shares $479.52 million -3.0%6.1%5.4 $133.20
8/31/20213,710,000 shares $488.64 million -12.9%6.2%5.4 $131.71
8/13/20214,260,000 shares $605.60 million +1.2%7.2%6.4 $142.16
7/30/20214,210,000 shares $713.68 million +2.2%7.1%6.5 $169.52
7/15/20214,120,000 shares $735.21 million +3.0%7.0%6.2 $178.45
6/30/20214,000,000 shares $710.56 million -11.3%6.8%6 $177.64
6/15/20214,510,000 shares $827.18 million +15.6%7.7%6.7 $183.41
5/28/20213,900,000 shares $694.71 million +8.0%6.7%6.2 $178.13
5/14/20213,610,000 shares $643.16 million -31.4%N/A5.4 $178.16
4/30/20215,260,000 shares $871.85 million +11.2%N/A7.4 $165.75
4/15/20214,730,000 shares $786.93 million +0.6%8.7%6.5 $166.37
3/31/20214,700,000 shares $782.50 million +3.8%8.7%6.5 $166.49
3/15/20214,530,000 shares $758.87 million +4.4%8.4%6.2 $167.52
2/26/20214,340,000 shares $741.01 million +5.3%8.0%6 $170.74
2/12/20214,120,000 shares $687.42 million +30.0%7.6%6 $166.85
1/29/20213,170,000 shares $517.50 million -2.2%5.8%5 $163.25
1/15/20213,240,000 shares $537.22 million -6.4%6.0%6.2 $165.81
12/31/20203,460,000 shares $569.38 million -0.6%6.4%6.7 $164.56
12/15/20203,480,000 shares $519.32 million -4.7%6.5%6.6 $149.23
11/30/20203,650,000 shares $522.97 million +1.1%6.8%5.1 $143.28
11/15/20203,610,000 shares $531.07 million -11.1%6.7%4.8 $147.11
10/30/20204,060,000 shares $591.26 million -2.6%7.6%5.5 $145.63
10/15/20204,170,000 shares $634.67 million -12.4%7.8%5.5 $152.20
9/30/20204,760,000 shares $678.73 million +30.4%8.9%6.1 $142.59
9/15/20203,650,000 shares $516.48 million +13.0%6.8%4.7 $141.50
8/31/20203,230,000 shares $434.08 million +4.5%6.1%4.7 $134.39
8/14/20203,090,000 shares $383.96 million -11.5%5.8%4.4 $124.26

JAZZ Short Interest - Frequently Asked Questions

What is Jazz Pharmaceuticals' current short interest?

Short interest is the volume of Jazz Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 5,730,000 shares of JAZZ short. 9.92% of Jazz Pharmaceuticals' shares are currently sold short. Learn More on Jazz Pharmaceuticals' current short interest.

What is a good short interest ratio for Jazz Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. JAZZ shares currently have a short interest ratio of 6.0. Learn More on Jazz Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Jazz Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Jazz Pharmaceuticals: Simplex Trading LLC, Wolverine Asset Management LLC, Quaker Wealth Management LLC, Jane Street Group LLC, Jane Street Group LLC, Simplex Trading LLC, Wolverine Asset Management LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Jazz Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.92% of Jazz Pharmaceuticals' floating shares are currently sold short.

Is Jazz Pharmaceuticals' short interest increasing or decreasing?

Jazz Pharmaceuticals saw a decline in short interest in July. As of July 15th, there was short interest totaling 5,730,000 shares, a decline of 2.4% from the previous total of 5,870,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Jazz Pharmaceuticals' float size?

Jazz Pharmaceuticals currently has issued a total of 60,511,000 shares. Some of Jazz Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jazz Pharmaceuticals currently has a public float of 57,780,000 shares.

How does Jazz Pharmaceuticals' short interest compare to its competitors?

9.92% of Jazz Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Jazz Pharmaceuticals: Axsome Therapeutics, Inc. (7.27%), Royalty Pharma PLC (5.04%), Corcept Therapeutics Incorporated (11.96%), Perrigo Company plc (4.61%), Supernus Pharmaceuticals, Inc. (9.11%), Pacira BioSciences, Inc. (12.15%), Nektar Therapeutics (6.88%), Omeros Corporation (24.29%), Assembly Biosciences, Inc. (0.76%), Cumberland Pharmaceuticals Inc. (0.08%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks.

What does it mean to sell short Jazz Pharmaceuticals stock?

Short selling JAZZ is an investing strategy that aims to generate trading profit from Jazz Pharmaceuticals as its price is falling. JAZZ shares are trading down $0.87 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Jazz Pharmaceuticals?

A short squeeze for Jazz Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of JAZZ, which in turn drives the price of the stock up even further.

How often is Jazz Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JAZZ, twice per month. The most recent reporting period available is July, 15 2025.




This page (NASDAQ:JAZZ) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners